MBChB, MMed (Clin Epi), FRACP
Special clinical interest
Genitourinary (Kidney, Bladder, Testicular and Prostate); Gastrointestinal (Oesophagus, Stomach, Liver, Pancreas and Colon); Brain and Melanoma.
Chemotherapy, Immunotherapy and Hormonal therapies.
Dr Gary Tincknell is a Medical Oncologist treating patients with genitourinary, gastrointestinal and brain cancers. He also treats patients with melanoma.
Dr Tincknell trained at the University of Leicester, graduating in 2010. After working in the UK for 2 years, he relocated to Sydney to continue his clinical training. He completed his specialty training in Medical Oncology at St George, Prince of Wales and Wollongong Hospitals, obtaining his fellowship in Medical Oncology from the Royal Australasian College of Physicians (FRACP) in 2020.
Dr Tincknell has a keen interest in clinical and translational research. He is the principal investigator on several clinical trials, aiming to improve the survival and side effects of patients undergoing cancer treatments. Gary, in his spare time, is completing a PhD at the University of Wollongong with his thesis on the clinical and molecular biomarkers of gastric and oesophageal cancers.
He is a senior clinical lecturer at the University of Wollongong.
Gary is a member of many professional societies including the Australasian Gastro-Intestinal Trials Group, Australian and New Zealand Urogenital and Prostate cancer trials group, Medical Oncology Group of Australia and Clinical Oncology Society of Australia.
Dr Tincknell consults and treats patients at the Southern Cancer Institute (Wollongong), Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre. He also treats patients at the Milton Ulladulla Hospital and Nowra Private Hospitals.
Research, Awards and Teaching Interests
Research: PhD- Clinical and molecular biomarkers of gastric and oesophageal cancers
Clinical trials: Multiple clinical trials ranging from early phase and international practice changing trials
Teaching: Clinical education of medical students, junior doctors and advanced trainees
- Tincknell G, Naveed A, Nankervis J, Mukhtiar A, Piper A-K, Becker TM, Chantrill L, Aghmesheh M, Vine KL, Ranson M, Brungs D. HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis. Cancers. 2022; 14(23):5754. https://doi.org/10.3390/cancers14235754
- Pavlakis N, Tincknell G, Lim LE, Muro K, Obermannova R, Lorenzen S, Chua YJ, Jackson C, Karapetis C, Price T, Chantrill L, Segelov E, Lordick F. European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. Therapeutic Advances in Medical Oncology. 2022;14. https://doi.org/10.1177/17588359221118874
- Tincknell G, Piper A-K, Aghmesheh M, Becker T, Vine KL, Brungs D, Ranson M. Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma. Cancers. 2021; 13(16):4097. https://doi.org/10.3390/cancers13164097
- Lim LE, Chan DL, Thomas D, Du Y, Tincknell G, Kuchel A, Davis A, Bailey DL, Pavlakis N, Cehic G, Macdonald W, Wyld D, Segelov E. Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. 2020; 11: 2636-2646. https://doi.org/10.18632/oncotarget.27659